Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COMBINATION PACLITAXEL (TAXOL(R))-CISPLATIN VS CYCLOPHOSPHAMIDE-CISPLATIN AS PRIMARY THERAPY IN PATIENTS WITH SUBOPTIMALLY DEBULKED ADVANCED OVARIAN-CANCER
Autore:
HOSKINS WJ; MCGUIRE WP; BRADY MF; KUCERA PR; PARTRIDGE EE; LOOK KY; CLARKEPEARSON DL; DAVIDSON M;
Indirizzi:
MEM SLOAN KETTERING CANC CTR,DEPT SURG,GYNECOL SERV,1275 YORK AVE NEWYORK NY 10021 CORNELL UNIV,COLL MED,DEPT OBSTET & GYNECOL NEW YORK NY 00000 EMORY UNIV,DEPT MED ATLANTA GA 30322 ROSWELL PK CANC CTR,STAT OFF,GYNECOL ONCOL GRP BUFFALO NY 00000 OREGON HLTH SCI UNIV,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL PORTLANDOR 97201 UNIV ALABAMA,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL BIRMINGHAM AL 35294 INDIANA UNIV,SCH MED,DIV OBSTET & GYNECOL INDIANAPOLIS IN 00000 DUKE UNIV,SCH MED,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL DURHAM NC 27706 WALTER REED ARMY MED CTR,DEPT PATHOL WASHINGTON DC 20307 WALTER REED ARMY MED CTR,AREA LAB SCI WASHINGTON DC 20307
Titolo Testata:
International journal of gynecological cancer
, volume: 7, anno: 1997, supplemento:, 1
pagine: 9 - 13
SICI:
1048-891X(1997)7:<9:CP(VC>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Keywords:
OVARIAN CANCER; PACLITAXEL-CISPLATIN; PACLITAXEL-CYCLOPHOSPHAMIDE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
5
Recensione:
Indirizzi per estratti:
Citazione:
W.J. Hoskins et al., "COMBINATION PACLITAXEL (TAXOL(R))-CISPLATIN VS CYCLOPHOSPHAMIDE-CISPLATIN AS PRIMARY THERAPY IN PATIENTS WITH SUBOPTIMALLY DEBULKED ADVANCED OVARIAN-CANCER", International journal of gynecological cancer, 7, 1997, pp. 9-13

Abstract

The Gynecologic Oncology Group initiated a study to evaluate combination paclitaxel (Taxol(R), Bristol-Myers Squibb Company)-cisplatin vs standard therapy with cyclophosphamide-cisplatin as primary therapy forpatients with suboptimally debulked advanced ovarian cancer. The 386 eligible patients were randomly assigned to treatment with either cisplatin 75 mg m(-2) plus cyclophosphamide 750 mg m(-2) or the same dose of cisplatin plus paclitaxel 135 mg m(-2) given over 24 h. Response totherapy was assessed in 216 patients with clinically measurable disease. In the standard-therapy arm, overall response was 60%, with a 31% rate of complete response. In the paclitaxel-based treatment group, the overall response was 73%, and 51% of patients achieved a complete response. Although neutropenia, fever, alopecia, and peripheral neuropathy were more common in the paclitaxel-treated patients, myelosuppression was generally brief and nonhematologic toxicities were mild. Both overall and progression-free survival significantly favored patients treated with paclitaxel-cisplatin: overall survival was 37.5 vs 24.4 months, and progression-free survival was 17.9 vs 12.9 months for the paclitaxel- and cyclophosphamide-treated groups, respectively. Paclitaxel-cisplatin offers prolonged survival and progression-free survival without increasing toxicity when used as first-line therapy for patients with suboptimally debulked ovarian cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/08/20 alle ore 10:58:00